SEARCH WITHIN CONTENT
Pavel Vlasov * / Vladimir Karlov / Irina Zhidkova / Aleksandr Chervyakov / Oleg Belyaev / Iosif Volkov / Diana Dmitrenko / Antonina Karas / Tatiana Kazennykh / Olga Miguskina / Anna Moskvicheva / Elena Paramonova / Irina Ponomareva
Citation Information : Journal of Epileptology. Volume 24, Issue 1, Pages 7-14, DOI: https://doi.org/10.1515/joepi-2016-0007
License : (CC BY 4.0)
Received Date : 05-May-2016 / Accepted: 22-June-2016 / Published Online: 24-June-2016
Introduction. Perampanel (PER) (Fycompa) 5'-(2-cyanophenyl)-1'-phenyl-2,3'-bipyridinyl-6'(1'H)-on is the newest antiepileptic drug and is the first-in-class selective non-competitive antagonist of ionotropic AMPA glutamate receptors of the postsynaptic neuronal membrane.
The aim was to summarize Russian experience in using PER in daily clinical practice, and for this purpose the results of its use as an add-on treatment for focal epilepsy were assessed retrospectively
Material and Method. The results of the study of PER efficacy and safety in 52 patients with refractory focal epilepsy are presented. Mean age was 28.9 } 14.0 years; proportion of male patients was 56%, duration of the disease over 10 years – 69.2%, symptomatic epilepsy – 76.9%, with frontal – 46.2% and temporal – 44.2% localization of epileptic lesion. Majority of patients – 71.2% started PER treatment after 3 preceding lines of therapy
Results. The baseline seizure frequency of all types was 127.3 } 82.3 per month; secondary generalized seizures – 6.7 } 1.9 per month. After PER was added, a significant decrease in seizure frequency was observed already during the first month, to 52.1 } 29.3 seizures per month (Sign test, p = 0.00001) for seizures of all types and to 3.7 } 1.7 (Sign test, p = 0.00001) for secondary generalized seizures. In an overwhelming majority of cases, duration of PER treatment was more than 6 months. In 58% of patients, seizure frequency decreased by more than 50% (responders). Seizure-free status for all seizure types was observed in 9% of cases at 12 month, and absence of secondary generalized seizures only was achieved in 31% of patients. Adverse events were observed in 30.1% of patients: aggression – 11.5% and drowsiness – 9.6%, with all other AEs observed more rarely. PER dose was reduced due to side effects in 7 patients (13.5%), and in 4 patients (7.7%) PER was discontinued. Average PER dose in adult patients was as low as 6 mg.
Conclusions. PER was effective in the treatment of refractory forms of focal epilepsy, reducing seizure frequency on average by 76% by the second month of treatment. In addition to a good clinical effect, PER demonstrated a rather acceptable and predictable safety profile.
Avakyan G.N.: Epidemiologiya epilepsii i optimizatsiya terapii fokalnykh epilepsiy [Epidemiology of epilepsy and optimization of treatment of focal epilepsies]. Epilepsiya i paroksizmalnye sostoyaniya (Epilepsy and paroxysmal states), 2014, 1: 3–5.
Belousova Y.D.: Effektivnost i perenosimost perampanela v kachestve dopolnitelnogo preparata u podrostkov s rezistentnoy partsialnoy epilepsiyey: rezultaty randomizirovannogo dvoynogo slepogo platsebo-kontroliruyemogo issledovaniya, provedennogo v Rossiyskoy Federatsii [Efficacy and tolerability of perampanel as an add-on treatment in teenagers with refractory partial epilepsy: the results of a randomized, double-blind, placebocontrolled study conducted in the Russian Federation]. Epilepsiya i paroksizmalnye sostoyaniya (Epilepsy and paroxysmal states), 2014, 1: 27–33.
French J.A., Krauss G.L., Biton V., Squillacote D., Yang H., Laurenza A. et al.: Adjunctive perampanel for refractory partial- onset seizures: randomized phase III study 304. Neurology, 2012, 79: 589–596.
French J.A., Krauss G.L., Steinhoff B.J., Squillacote D., Yang H., Kumar D., Laurenza A. et al.: Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia, 2013, 54: 117–125.
French J.A., Krauss G.L., Wechsler R.T., Wang X.F., DiVentura B., Brandt C. et al.: Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy. A randomized trial. Neurology, 2015, 85: 1–8.
Fycompa®. Package leaflet of the medicinal product for human use dated 29.06.2015. Registration number: ЛП-002200. International nonproprietary name: Perampanel.
Hanada T., Hashizume Y., Tokuhara N., Takenaka O., Kohmura N., Ogasawara A. et al.: Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia, 2011, 52: 1331–1340.
Karlov V.A.: Farmakorezistentnost i tolerantnost (Pharmacoresistance and tolerance). In the book “Epilepsiya u detey i vzroslykh zhenshchin i muzhchin. Rukovodstvo dlya vrachey” [Epilepsy in children and adult women and men. Guide for doctors]. M., Meditsina, 2010, 667–676.
Krauss G.L., Perucca E., Ben-Menachem E., Kwan P., Shih J.J., Clément J.F. et al.: Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307. Epilepsia, 2014, 55: 1058–1068.
Krauss G.L., Serratosa J.M., Villanueva V., Endziniene M., Hong Z., French J. et al.: Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology, 2012, 78: 1408–1415.
Meador K.J., Yang H., Piña-Garza J.E., Laurenza A., Kumar D., Wesnes K.A.: Cognitive effects of adjunctive perampanel for partial-onset seizures: A randomized trial. Epilepsia, 2016, 57: 243–251.
Mula M., Kanner A.M., Schmitz B., Schachter S.: Antiepileptic drugs and suicidality: An expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia, 2013, 54: 199–203.
Patsalos P.N.: Drug Interactions With the Newer Antiepileptic Drugs (AEDs) – Part 1: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs. Clinical Pharmacokinetics, 2013a, 52: 927–966.
Patsalos P.N.: Drug Interactions with the Newer antiepileptic drugs (AEDs) – Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-epilepsy Disorders. Clinical Pharmacokinetics, 2013b, 52: 1045–1061.
Patsalos P.N., Gougoulaki M., Sander J.W.: Perampanel Serum Concentrations in Adults With Epilepsy: Effect of Dose, Age, Sex, and Concomitant Anti-Epileptic Drugs. Ther Drug Monit., 2016, Jun 38 (3): 358–364. doi: 10.1097/FTD.0000000000000274.
Renroe B., Yang H., Williams B.: Interim efficacy and safety analysis of adjunctive perampanel in the adolescent population from the extension phase of 3 double-blind, placebo-controlled phase 3 (core) studies in patients with refractory partial-onset seizures. 42nd Annual Meeting of the Child Neurology Society; 30 Oct.–2 Nov. 2013, Austin, TX, USA, 2013.
Rogawski M.A.: Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents, 2011, 11: 56–63.
Steinhoff B.J., Bacher M., Bast T., Kornmeier R., Kurth C., Scholly J. et al.: First clinical experiences with perampanel – the Kork experience in 74 patients. Epilepsia, 2014а, 55 (Suppl. 1): 16–18.
Steinhoff B.J., Hamer H., Trinka E., Schulze-Bonhage A., Bien C., Mayer T. et al.: A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Res., 2014b, 108: 986–988.
Vlasov P.N.: Effektivnost i perenosimost: rezultaty dvoynogo slepogo platsebo-kontroliruyemogo i prodlennogo otkrytogo issledovaniya otsenki dolgovremennoy bezopasnosti i effektivnosti perampanela v RF [Efficacy and tolerability: double-blind, placebo- controlled, and extended open study to evaluate long-term safety and efficacy of perampanel in the Russian Federation]. Epilepsiya i paroksizmalnye sostoyaniya (Epilepsy and paroxysmal states), 2014, 1: 10–12.